Digging through the data to find chart success.
More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody, which suggests the drug boasts similar safety and efficacy in non ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Gabriella DePinho Gabriella DePinho is a writer covering trending products.
It’s Not Just Iran. Trump Is Flailing on Multiple Fronts. The president is on a losing streak, and even some of his aides are dismayed by his choices.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results